Merck and AstraZeneca formed a global strategic oncology collaboration to co-develop and co-commercialize Lynparza (olaparib) and selumetinib. Merck paid $1.6B upfront plus $750M for license options, with up to $6.15B in regulatory and sales milestones. The companies share development costs and profits for both solo and combination therapies with their respective PD-1/PD-L1 agents.
Key facts
AnnouncedJul 27, 2017
Deal value$8.5B
Deal typeCo-Development
Therapeutic areaOncology
IndicationsOvarian Cancer, Breast Cancer, Prostate Cancer, NSCLC